Down 25% in a month, the Incannex share price is now halted. Here's why

A key update awaits the market from Incannex.

| More on:
A dollar sign embedded in ice, indicating a share price freeze or trading halt

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex Healthcare shares are on the backburner today pending a company announcement 
  • Prior to the halt they were resting at 38 cents apiece. The company intends to release readouts from a recent clinical trial 
  • In the last 12 months, the Incannex Healthcare share price has held a 24% gain 

Shares of Incannex Healthcare Ltd (ASX: IHL) are on ice today pending a company announcement. Before being placed on the backburner, the Incannex share price rested at 38 cents apiece.

Zooming out, shares of the cannabis player have faltered more than 39% this year to date, amid a violent selloff in growth-type shares in 2022.

In wider market moves, the S&P/ASX 200 Health Care Index (ASX: XHJ) has crumbled today and is now more than 3% in the red, bringing losses to 12% this year.

Meanwhile, in the US, the Nasdaq Composite Index (Nasdaq) fell sharply overnight, marking its largest single-day drop since 2020.

Investors sold off shares in the tech-biased Nasdaq after US Federal Reserve chair Jerome Powell raised the Fed's base interest rate by 0.5 percentage points, in an effort to control inflationary pressures.

Why is the Incannex share price halted?

The company requested its shares be put on ice in lieu of a market-sensitive announcement regarding upcoming study readouts.

"[Incannex] requests a trading halt to be applied to its securities…pending an announcement by the company regarding results of its extensive preclinical study assessing IHL-216A in a sports concussion model," it said in the filing.

"The Company requests that the trading halt remains in place until the earlier of the commencement of normal trading on May 10, 2022 or the release of the announcement."

Naturally the ASX awarded Incannex its request and, as such, investors must now wait until the company posts its next update on or before May 10.

Earlier in the year, investors appeared rattled by Incannex's decision to acquire APIRx Pharmaceutical USA, LLC for US$93 million.

Even though it now claims a total addressable market of more than US$400 billion globally, investors didn't appear as thrilled.

As such, losses have continued into May and shares have stooped from a high of 70 cents in March.

Incannex Healthcare share price snapshot

In the last 12 months, the Incannex Healthcare share price has held a 24% gain. However, it has collapsed into the red on each of the shorter time frames.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man looking happy and excited as he looks at his mobile phone.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on big news

This stock is getting a lot of attention from investors on Wednesday. But why?

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

How much further upside is there for Mesoblast shares after soaring 23% in a month?

Could FDA approval send this healthcare stock towards further gains?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Is this soaring ASX 200 healthcare share just getting started?

If its lead therapy gets US approval, the stock can continue to climb.

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Own CSL shares? Here are the key dates for 2026

It's been a bad year for CSL shares. What's ahead in 2026?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Healthcare Shares

Is Sigma Healthcare share a healthy buy, after hitting new lows?

The Chemist Warehouse merger and ageing population might boost this stock's appeal.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »